Author: Ortega Rafael

Ortega Rafael brings a distinctive perspective to technology journalism through his specialized background in industrial computing and automation systems, where he deciphers complex technical concepts for broader audiences. His analytical approach to emerging technologies—particularly industrial IoT and smart infrastructure—stems from hands-on experience with embedded systems and manufacturing environments. Rafael's writing consistently explores the intersection of hardware innovation and digital transformation, offering readers uncommon insights into how foundational technologies evolve into disruptive solutions. This unique vantage point, shaped by his technical background, enables him to anticipate industry shifts with remarkable accuracy while maintaining accessible commentary on the technologies reshaping modern industrial landscapes.
BusinessPolicy

Former NSW Premier’s Lobbying Firm Sees Surge in Property Clients Amid Government Planning Reforms

Lobbying firm Iemma Patterson Premier Advisory has experienced significant growth in property sector clients following the election of Chris Minns as NSW Premier. The firm’s connections to the current government and its planning overhaul have reportedly attracted numerous development companies seeking influence on housing policy.

Lobbying Firm’s Client Base Expands Amid Planning Changes

Morris Iemma’s lobbying firm has reportedly experienced substantial growth in its property development client roster since his political mentee Chris Minns became New South Wales premier, according to government records and media reports. Iemma Patterson Premier Advisory (IPPA), where the former Labor premier and former Liberal MP Chris Patterson serve as principals, has added at least 40 property sector clients since the March 2023 election.

by Ortega Rafael
BusinessPolicy

Trump Administration’s Pharmaceutical Deals Signal Major Policy Shift in Drug Pricing

Pharmaceutical giants Pfizer and AstraZeneca have reached landmark agreements with the Trump Administration, committing to significant drug price reductions and substantial domestic investments. The deals, reportedly negotiated under tariff pressure, represent a new approach to pharmaceutical policy that ties affordability to manufacturing reshoring.

Pharmaceutical Giants Yield to Administration Pressure

Two major pharmaceutical companies have reached significant agreements with the Trump Administration that analysts suggest could reshape how drug pricing is approached in the United States. According to reports, both Pfizer and AstraZeneca agreed to substantial price reductions and domestic investment commitments under a new framework that links affordability to manufacturing reshoring.

by Ortega Rafael